| Literature DB >> 26843711 |
Alex J Thompson1, Jacinta A Holmes2.
Abstract
Chronic hepatitis C infection causes cirrhosis, liver failure and hepatocellular carcinoma, and is the most common indication for liver transplantation. Hepatitis C is curable and complications can be prevented. Until recently, treatment regimens involved peginterferon alfa. Although effective, their widespread use is limited by treatment-related toxicity. A number of direct-acting drugs for hepatitis C, such as sofosbuvir, have recently been developed and target multiple steps in the viral life cycle. These drugs are used in combination in interferon-free regimens. Short courses are highly effective with minimal toxicity.Entities:
Keywords: asunaprevir; daclatasvir; hepatitis C; peginterferon; protease inhibitors; ribavirin; sofosbuvir
Year: 2015 PMID: 26843711 PMCID: PMC4674032 DOI: 10.18773/austprescr.2015.068
Source DB: PubMed Journal: Aust Prescr ISSN: 0312-8008